Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 1Phase 1/2 1

Status

Completed 6

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Classical hematology 2Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 2046Neoplasms 1460Carcinoma, Non-Small-Cell Lung 1364Prostatic Neoplasms 1106Multiple Myeloma 873Leukemia, Myeloid, Acute 772Colorectal Neoplasms 713Neoplasm Metastasis 704Lung Neoplasms 697Melanoma 688Lymphoma 666Leukemia 596Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 535Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Recurrence 474Myelodysplastic Syndromes 425Lymphoma, Follicular 418Carcinoma, Renal Cell 412Head and Neck Neoplasms 408Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 376Hodgkin Disease 354Carcinoma, Hepatocellular 333Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

fostamatinib 3romiplostim 2eltrombopag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Purpura, Thrombocytopenic, Idiopathic × Clear all
NCT02077192 2023-12-11

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Rigel Pharmaceuticals

Phase 3 Completed
123 enrolled 11 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT01957176 2022-12-30

A Rollover Study to Provide Continued Treatment With Eltrombopag

Novartis

Phase 4 Completed
22 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myeloid, Acute, Purpura, Thrombocytopenic, Idiopathic

NCT02076399 2019-02-12

FIT

Rigel Pharmaceuticals

Phase 3 Completed
76 enrolled 17 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT02076412 2019-01-25

FIT

Rigel Pharmaceuticals

Phase 3 Completed
74 enrolled 17 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT01444417 2017-02-09

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Amgen

Phase 3 Completed
62 enrolled 16 charts 1 FDA
Classical hematology

Purpura, Thrombocytopenic, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic

NCT00515203 2014-07-25

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Amgen

Phase 1/2 Completed
22 enrolled 13 charts 1 FDA

Purpura, Thrombocytopenic, Purpura, Thrombocytopenic, Idiopathic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡